Rhythm Pharmaceuticals Advances Obesity Treatment with RM-718 Study

Rhythm Pharmaceuticals ((RYTM)) announced an update on their ongoing clinical study.

Rhythm Pharmaceuticals is conducting a clinical study titled A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Hypothalamic Obesity (HO). The study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of RM-718 in individuals with obesity and those with hypothalamic obesity (HO). This research is significant as it addresses potential treatment options for obesity-related conditions.

The intervention being tested is RM-718, a drug administered via subcutaneous injection. It is designed to be given in single or multiple ascending doses to assess its effects on participants.

The study follows an interventional design with a randomized allocation and parallel intervention model. It employs triple masking, meaning that the participant, care provider, and investigator are blinded to the treatment allocation. The primary purpose of the study is treatment-focused.

The study began on March 5, 2024, with an estimated completion date yet to be announced. The latest update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and assessing its timeline for potential market entry.

This update could positively influence Rhythm Pharmaceuticals’ stock performance by demonstrating progress in their research pipeline, potentially boosting investor confidence. The study’s outcomes might also impact the competitive landscape in obesity treatment, where advancements are keenly watched by industry players.

The study is ongoing, with further details available on the ClinicalTrials portal.